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Abstract: Purpose: The aim of this study was to compare the efficacy and safety of a single 
intra-articular injection of adipose mesenchymal stem cells (aMSCs) versus plasma rich  
in growth factors (PRGF) as a treatment for reducing symptoms in dogs with hip 
osteoarthritis (OA). Methods: This was a randomized, multicenter, blinded, parallel group. 
Thirty-nine dogs with symptomatic hip OA were assigned to one of the two groups, to 
receive aMSCs or PRGF. The primary outcome measures were pain and function 
subscales, including radiologic assessment, functional limitation and joint mobility. The 
secondary outcome measures were owners’ satisfaction questionnaire, rescue analgesic 
requirement and overall safety. Data was collected at baseline, then, 1, 3 and 6 months 
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post-treatment. Results: OA degree did not vary within groups. Functional limitation, range 
of motion (ROM), owner’s and veterinary investigator visual analogue scale (VAS), and 
patient’s quality of life improved from the first month up to six months. The aMSCs group 
obtained better results at 6 months. There were no adverse effects during the study. Our 
findings show that aMSCs and PRGF are safe and effective in the functional analysis at  
1, 3 and 6 months; provide a significant improvement, reducing dog’s pain, and improving 
physical function. With respect to basal levels for every parameter in patients with hip OA, 
aMSCs showed better results at 6 months. 
Keywords: adipose derived mesenchymal stem cells; plasma rich in growth factors; 
osteoarthritis; dog; hip  
 
1. Introduction 
Osteoarthritis (OA) is a very common degenerative disease affecting the articular cartilage in  
both human [1] and veterinary medicine [2,3]. This condition affects 15% of the world population, 
amounting to colossal health-care costs [4], and has a great impact on a patient’s quality of life [5]. 
The current therapeutic approaches focus on preventing or at least delaying the structural and 
functional changes of OA. The use of stem cell-based therapies and Platelet Rich Plasma (PRP) for 
repair and regeneration in OA has become a new avenue of treatment as an alternative to the more 
aggressive therapies [6–10]. 
Stem cells may be of embryonic origin (ESCs) or adult (ASCs). Adult stem cells have a much lower 
capacity than embryonic stem cells to self-renew and differentiate along multiple lineage pathways. 
However, adult stem cells are immunocompatible, and their use is not restricted by the ethical concerns 
associated with embryo-derived cells. Apart from the ethical concerns embryonic cells are known to 
raise, they have also been shown to demonstrate uncontrolled growth [11,12]. In contrast, adult stem 
cells, including mesenchymal stem cells (MSCs), are a very good option as they are present in a 
number of postnatal organs and connective tissues, and are not subject to the same restrictions as the 
embryonic cells [13]. Mesenchymal stem cells can be easily isolated from many adult tissues such as 
bone marrow, placenta [14], umbilical cord [15], skeletal muscle [16], synovium [17], synovial  
fluid [18], and adipose tissue [8,19] among others. An increasing amount of studies are using adipose 
tissue derived mesenchymal cells (aMSCs) in the treatment of OA, as large quantities are easily 
harvested with little donor site morbidity or patient discomfort, as well as demonstrating the ability to 
differentiate into chondrocytes, osteocytes and adipocytes [20]. It has been shown that autologous stem 
cells have an affinity for damaged joint tissue; recent studies have confirmed that stem cells have  
the ability to localize and participate in the repair of damaged joint structures [21]. Recently, it was 
published that aMSC therapy was found to be an appropriate treatment for hip joints in dogs, 
improving the dog’s gait and ability to live a more normal life [22]. 
One of the most popular methods used to biologically enhance healing in the fields of orthopedic 
surgery and sports medicine includes the use of autologous blood products, particularly, PRP [23]. PRP 
is defined as the volume of autologous plasma having a platelet concentration over baseline [24–26], 
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and is also referred to as plasma rich in growth factors (PRGF), PRP-gel, platelet gel or platelet  
clot [27–29]. Under normal circumstances, platelets are the first cell type to arrive at the tissue injury 
site and are particularly active in the early inflammatory phases [30]. Several studies describe the  
use of PRP as an effective and safe method in the treatment of pain and joint dysfunction in OA.  
The use of PRGF (PRGF-Endoret; BTI Biotechnology Institute, Vitoria, Spain), an autologous PRP 
characterized by the absence of leukocytes and proinflammatory cytokines and the presence of  
a specific dose of platelets and growth factors [28], has been demonstrated to achieve significant 
improvement in humans with knee OA [5,31] and also in dogs with OA [32]. 
Currently, the effectiveness of these two therapies has been demonstrated for the treatment of OA, 
however in the literature, there are no studies comparing the results of these two treatments with each 
other. The aim of this study was to compare the efficacy and safety in a randomized, clinical trial of  
a single intra-articular injection of adipose mesenchymal stem cells (aMSCs) (Dog-Stem, Fat-Stem, 
Aalst, Belgium) versus a single intra-articular injection of plasma rich in growth factors (PRGF) 
(PRGF-Endoret, BTI Biotechnology Institute, Vitoria-Gasteiz, Araba, Spain) as a treatment for 
reducing symptoms in dogs with hip osteoarthritis (OA), assessing the effectiveness of each treatment 
and determine the advantages and disadvantages of each. 
2. Results and Discussion 
2.1. Results 
2.1.1. Animal Population 
A total of 70 patients with lameness in the legs were assessed for eligibility. Only 53 of them 
presented a hip problem, from which 14 were not included, as they did not meet the inclusion criteria. 
Finally, 39 animals were screened, and randomized into their corresponding group. Four were lost to 
follow up, 1 in the aMSCs group and 3 in the PRGF group (Figure 1).  
Animals were recruited from January 2002 to January 2003. Animals included in the study, 
attended clinic visits at the time of randomization (baseline) and at 1, 3 and 6 months after receiving 
the treatment. 
The mean age and weight of the patients was 53 ± 43 months (age range: 8–135 months), and  
34.9 ± 12.8 kg (weight range: 18.3–66.2 kg) in the aMSCs group and 93 ± 35.5 (age range: 18–66) and 
36.5 ± 10.6 kg (weight range 20–62.8 kg), in the PRGF group. Twenty-four of the patients were male, 
10 in aMSCs and 14 in PRGF, and 11 were female, 8 in the aMSCs group and 3 in the PRGF group 
(Table 1).  
2.1.2. Pain Assessment 
The VAS results were calculated as % change from baseline at all treatment time points (Figure 2). 
Results of pain assessment (VAS scores) measured at baseline and outcomes for the entire population 
are summarized in Table 2. 
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Figure 1. Enrollment and outcomes.  
 
Table 1. Baseline characteristics of patients assessed. 
Characteristic aMSCs PRGF p-Value 
Age (months) 53 ± 43 (8–135) 93 ± 35.5 (18–66) 0.007 
Weight 34.9 ± 12.8 (18.3–66.2) 36.5 ± 10.6 (20–62.8) 0.805 
Gender (male-female) 10-8 14-3 0.201 
Radiographic Osteoarthritis degree Bioarth Score *  15.47 ± 6.02 (13.37–17.57) 17.36 ± 3.8 (16.07–18.65) 0.259 
Functional limitation 5.88 ± 2.83 (2–11) 8.22 ± 3.39 (1–14) 0.003 
Joint mobility 4.18 ± 0.63 (3–5) 3.92 ± 0.84 (2–6) 0.131 
Muscle atrophy 1.05 ± 0.55572 1.0526 ± 0.62126 0.890 
Owner Vas Score 28.29 ± 14.49 (6.57–72.37) 42.55 ± 20.52 (9.21–72.37) 0.023 
Patients  18 17  
Quantitative variables are expressed as mean ± standard deviation (range). p < 0.05 is considered statistically 
significant. * The Bioarth score is an index of severity for hip mobility that includes 4 subscales (radiographic 
findings (0–21 points), functional limitation (0–23), joint mobility (0–7 points) and muscle atrophy (0–2 points). 
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In the owner’s pain assessment, significant differences were observed in the aMSCs and PRGF 
groups between baseline and 1, 3 and 6 months post-treatment, with no statistically significant 
differences between them. 
In the investigator assessment, significant differences were observed in both groups between 
baseline and all other follow-up time points. Comparing both treatments, there were only differences  
at 6 months post-infiltration, where patients treated with aMSCs showed more pain relief than those 
treated with PRGF. 
Figure 2. Changes in VAS from baseline value assessed by the owner (A) and the 
investigator (B). The changes in VAS which differed significantly with baseline (p < 0.05) 
are marked as *. The circles, both green and blue, correspond to anomaly/outlier data 
included in the statistical study. The blue asterisk corresponds to an outlier, to which the 
Dixon Q test was applied in order to confirm deletion of the value from the database. 
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Table 2. The mean VAS (±SD) assessed by the dog owners and by the investigator at each 
time point. For statistical purposes, the Kruskal Wallis Test was applied (Spss Statistics  
for MAC, version 20, IBM, Madrid, Spain). Differences between groups are shown as  
p-value between groups. p < 0.05 is considered statistically significant.  
Variable Time Group N Mean 
Std. 
Deviation
95% Confidence Interval for Mean
Minimum Maximum 
p-Value between
Groups Lower Bound Upper Bound 
Owner VAS 
baseline 
aMSCs 34 28.6353 14.33904 23.6322 33.6384 6.57 53.94 
0.001 PRGF 36 42.9756 20.61379 36.0009 49.9503 9.21 72.37 
Total 70 36.0103 19.13089 31.4487 40.5719 6.57 72.37 
1 month 
aMSCs 34 15.4312 11.03277 11.5817 19.2807 0.00 48.68 
0.000 PRGF 36 27.5978 13.61288 22.9918 32.2037 5.92 59.21 
Total 70 21.6883 13.77408 18.4040 24.9726 0.00 59.21 
3 months 
aMSCs 34 17.5500 15.87660 12.0104 23.0896 1.31 57.89 
0.014 PRGF 36 27.4081 16.72219 21.7501 33.0660 4.60 72.37 
Total 70 22.6199 16.94175 18.5802 26.6595 1.31 72.37 
6 months 
aMSCs 30 16.8620 13.55143 11.8018 21.9222 2.63 51.31 
0.046 PRGF 34 24.6088 16.43983 18.8727 30.3450 0.00 56.58 
Total 64 20.9775 15.53332 17.0974 24.8576 0.00 56.58 
Veterinarian VAS 
baseline 
aMSCs 34 23.8200 10.77498 20.0604 27.5796 6.57 50.66 
0.000 PRGF 36 32.9692 9.88435 29.6248 36.3136 10.60 48.68 
Total 70 28.5253 11.23820 25.8456 31.2049 6.57 50.66 
1 month 
aMSCs 34 14.0894 6.38365 11.8621 16.3168 6.57 32.89 
0.000 PRGF 36 24.8964 7.74936 22.2744 27.5184 8.00 42.76 
Total 70 19.6473 8.91895 17.5206 21.7739 6.57 42.76 
3 months 
aMSCs 34 10.8635 5.89049 8.8082 12.9188 3.95 26.31 
0.000 PRGF 36 22.0383 7.50788 19.4980 24.5786 6.00 40.79 
Total 70 16.6106 8.76544 14.5205 18.7006 3.95 40.79 
6 months 
aMSCs 32 9.5306 5.77949 7.4469 11.6144 3.95 29.60 
0.000 PRGF 34 24.8297 8.75538 21.7748 27.8846 6.00 50.00 
Total 66 17.4120 10.68689 14.7848 20.0391 3.95 50.00 
2.1.3. Degree of Osteoarthritis Based on the Radiographic Findings  
When OA degree was categorized at baseline, 3 patients had mild OA, 2 moderate OA and  
13 severe OA in the aMSCs group. However in the PRGF group, 5 patients presented moderate OA 
and 14 severe OA. There were no significant differences between groups. Except for 1 dog in the 
aMSCs group that at one month presented severe OA, the rest of the dogs’ radiographic scores  
at 6 months were the same as the scores at baseline in both groups. 
2.1.4. Bioarth Scale Assessment 
Global Scores of all the variables assessed with the Bioarth scale for hip OA in both groups at 
baseline and its outcomes are summarized in Table 3. 
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Table 3. Mean ± SD of the functional limitation, joint mobility and range of motion, at 
baseline, one, three and six months after treatment. Kruskal-Wallis results between groups. 
* Differences with baseline.  
Variable Time Group N Mean Std. Deviation
95% Confidence Interval  
for Mean Minimum Maximum 
p-Value 
between 
Groups Lower Bound Upper Bound
OA degree 
baseline 
aMSCs 34 15.47 6.02 13.37 17.57 3.00 21.00 
0.259 PRGF 36 17.36 3.80 16.07 18.65 10.00 21.00 
Total 70 16.44 5.06 15.24 17.65 3.00 21.00 
1 month 
aMSCs 34 15.62 6.11 13.49 17.75 3.00 21.00 
0.339 PRGF 36 17.36 3.80 16.07 18.65 10.00 21.00 
Total 70 16.51 5.10 15.30 17.73 3.00 21.00 
3 months 
aMSCs 34 15.74 6.16 13.59 17.88 3.00 21.00 
0.402 PRGF 36 17.39 3.81 16.10 18.68 10.00 21.00 
Total 70 16.59 5.12 15.36 17.81 3.00 21.00 
6 months 
aMSCs 32 15.75 6.44 13.43 18.07 3.00 21.00 
0.714 PRGF 34 17.18 3.82 15.84 18.51 10.00 21.00 




aMSCs 34 5.88 2.83 4.90 6.87 2.00 11.00 
0.003 PRGF 36 8.22 3.39 7.08 9.37 1.00 14.00 
Total 70 7.09 3.32 6.29 7.88 1.00 14.00 
1 month 
aMSCs 34 2.85 * 1.94 2.18 3.53 0.00 7.00 
0.009 PRGF 36 4.56 * 2.75 3.62 5.49 0.00 10.00 
Total 70 3.73 2.52 3.13 4.33 0.00 10.00 
3 months 
aMSCs 34 2.26 * 1.75 1.66 2.87 0.00 6.00 
0.181 PRGF 36 3.33 * 2.95 2.34 4.33 0.00 12.00 
Total 70 2.81 2.48 2.22 3.41 0.00 12.00 
6 months 
aMSCs 30 1.80 * 1.54 1.22 2.38 0.00 5.00 
0.004 PRGF 34 3.71 * 2.76 2.74 4.67 0.00 9.00 




aMSCs 34 4.18 0.63 3.96 4.39 3.00 5.00 
0.131 PRGF 36 3.92 0.84 3.63 4.20 2.00 6.00 
Total 70 4.04 0.75 3.86 4.22 2.00 6.00 
1 month 
aMSCs 34 2.4 * 1.23 1.98 2.84 0.00 4.00 
0.057 PRGF 36 2.97 * 0.88 2.68 3.27 1.00 4.00 
Total 70 2.70 1.09 2.44 2.96 0.00 4.00 
3 months 
aMSCs 34 1.38 * 1.52 0.85 1.91 0.00 4.00 
0.000 PRGF 36 2.75 * 1.02 2.40 3.10 1.00 4.00 
Total 70 2.09 1.45 1.74 2.43 0.00 4.00 
6 months 
aMSCs 32 1.09 * 1.40 0.59 1.60 0.00 4.00 
0.000 PRGF 34 2.82 * 1.00 2.47 3.17 1.00 4.00 
Total 66 1.98 1.48 1.62 2.35 0.00 4.00 
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Table 3. Cont. 
Variable Time Group N Mean Std. Deviation
95% Confidence Interval  
for Mean Minimum Maximum
p-Value 
between 





aMSCs 34 32.56 5.37 30.69 34.44 25.00 47.00 
0.609 PRGF 36 32.42 3.07 31.38 33.46 27.50 41.00 
Total 70 32.49 4.31 31.46 33.52 25.00 47.00 
1 month 
aMSCs 34 33.51 * 4.97 31.78 35.25 27.00 45.00 
0.005 PRGF 36 32.56 3.24 31.46 33.65 26.00 40.00 
Total 70 33.02 4.17 32.03 34.01 26.00 45.00 
3 months 
aMSCs 34 33.26 * 4.40 31.73 34.80 28.00 43.00 
0.984 PRGF 36 32.34 3.33 31.21 33.46 25.00 41.00 
Total 70 32.79 3.89 31.86 33.71 25.00 43.00 
6 months 
aMSCs 32 33.98 * 4.51 32.36 35.61 27.00 43.00 
0.000 PRGF 34 32.50 3.35 31.33 33.67 26.00 40.00 




aMSCs 34 64.12 12.06 59.91 68.33 40.00 90.00 
0.000 PRGF 36 75.61 12.22 71.48 79.75 54.00 95.00 
Total 70 70.03 13.37 66.84 73.22 40.00 95.00 
1 month 
aMSCs 34 96.65 * 13.21 92.04 101.26 60.00 125.00 
0.002 PRGF 36 87.69 * 11.71 83.73 91.66 55.00 105.00 
Total 70 92.04 13.16 88.90 95.18 55.00 125.00 
3 months 
aMSCs 34 103.71 * 12.26 99.43 107.98 60.00 125.00 
0.000 PRGF 36 92.67 * 11.35 88.83 96.51 68.00 115.00 
Total 70 98.03 12.96 94.94 101.12 60.00 125.00 
6 months 
aMSCs 32 107.09 * 8.56 104.01 110.18 90.00 122.00 
0.000 PRGF 34 90.50 * 11.24 86.58 94.42 60.00 105.00 
Total 66 98.55 12.99 95.35 101.74 60.00 122.00 
Functional Limitation 
Both groups showed significant improvement in functional limitation at all the times evaluated. 
There were significant differences between groups at baseline (p = 0.003), where PRGF presented 
more limitation to normal life than the aMSCs group; at 1 month this difference was maintained  
(p = 0.009), but at 3 months the quality of life was similar in both groups (p = 181), moreover  
at 6 months aMSCs continued with a better score in functional limitation, whereas PRGF started to 
decrease (p = 0.004) (Figure 3). 
Joint Mobility 
In the overall joint mobility, both groups improved significantly, showing differences to baseline at 
each time point. In addition, by 3 and 6 months, joint mobility in the aMSCs group was significantly 
higher than the PRGF group (p < 0.001 at both times). 
Regarding the range of motion (ROM), significant improvement was noted in both groups, 
obtaining significant differences compared to baseline.  
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Figure 3. Evolution of functional limitation (range: 0–23) in dogs after aMSCs or PRGF 
treatment at the 6-months follow up period. The changes which differed significantly with 
baseline (p < 0.05) are marked as *. Statistically significant differences between groups  
are marked as †. Circles, both green and blue, correspond to outlier included in the 
statistical study. 
 
Regarding the differences between groups there were significant differences from baseline (p = 0.001) 
with greater range of motion noted in the PRGF group, but since the first visit, animals from the aMSCs 
group obtained better results at 1, 3 and 6 months (p = 0.002; p < 0.001; p < 0.001; respectively), 
which indicates that the aMSCs group had a much greater increase in range of motion (Figure 4).  
Muscle Atrophy 
In the muscle atrophy assessment, neither of the two groups demonstrated significant differences at 
the different control periods. Compared with baseline, aMSCs group presented significant differences 
at 1 (p = 0.002), 3 (p = 0.048) and 6 (p < 0.001) months. In contrast, in the PRGF group muscle mass 
remained constant throughout the study. 
2.1.5. Overall Satisfaction with Treatment 
Fourteen and 9 animals from the aMSCs and PRGF groups, respectively, were treated with NSAIDs 
and nutraceuticals. Regarding treatment efficacy after the intra-articular injection of aMSCs or PRGF, 
satisfaction was high in both groups. 
According to the dog owners, quality of life improved for patients in both groups between baseline 
and 6 months in aMSCs (p = 0.004) and in PRGF (p = 0.001) groups. However, statistically significant 
differences between groups were shown at 6 months, where the aMSCs group scored higher than the 
PRGF group (p = 0.028).  
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In all cases, at the end of the treatment, owners were asked if they would use the same treatment 
again for their pets, and all of them responded positively.  
Figure 4. Evolution of joint mobility (range: 0–7) in dogs after aMSCs or PRGF treatment 
at the 6-months follow up period. The changes which differed significantly with baseline  
(p < 0.05) are marked as *. Statistically significant differences between groups are marked 
as †. The green circle is an outlier included in the statistics study. 
 
2.1.6. Safety Assessment 
Two adverse events, one in the aMSCs group and one in the PRGF group, were reported during the 
study. The adverse effect was mild and no differences were observed between groups (p = 0.671). The 
owners of the two animals reported pain post-injection and prolonged the NSAID treatment for 2 days 
in the aMSCs group, and 4 days in the PRGF group, with no significant differences between them. 
2.1.7. Requirement of Rescue Analgesia 
At 3 months, 1 dog in the aMSCs and 2 in the PRGF group were given meloxicam as rescue 
analgesic, without significant differences between them (p = 0.365), and at 6 months none of the dogs 
required analgesic in the aMSCs group and 2 animals did in the PRGF group, also without significant 
differences (0.064). 
  




The results from this randomized trial show that a single intra-articular injection of aMSCs is 
significantly more effective than one intra-articular injection of PRGF in reducing pain and improving 
functional limitation and quality of life in dogs with hip OA. To the author’s knowledge, the present 
study is the first that showed that both treatments reported good results from the first month  
post-treatment and up to six months, although better results were subjectively observed at 6 months in 
patients treated with aMSCs. The data obtained in the present study supports the use of these therapies 
as a treatment for OA. 
Among the wide variety of sources for adult mesenchymal cells [33] in this study MSCs were 
obtained from adipose tissue due to the ease of extraction and the absence of complications associated 
with this process [13,34]. Likewise, adipose tissue is a very rewarding source of mesenchymal cells, 
which are easily harvested and expanded in culture and have a high proliferation rate [19], capable of 
differentiation into chondrocytes, osteocytes and adipocytes [20]. 
The main adipose tissue harvest areas in previous studies in dogs are the falciform ligament [35], 
lateral thoracic area [36], caudal scapular region [37], intra-abdominal or subcutaneous fat obtained 
during ovariohysterectomy surgery [38,39] gluteal fat [40], and inguinal region [41,42]. In the current 
study fat was harvested from the inguinal area due to easy surgical access, the abundant collection and 
discrete scarring with no postoperative complications in any patients. 
The use of PRP products especially PRGF technology has been extended to the treatment of OA in 
single and in serial repeated injections over time [5,10,31,32,43]. The autologous growth factors and 
proteins released from the fibrin scaffold may play an important role in the repair or regeneration of 
the damaged cartilage [5]. In the current study, a single injection of PRGF was opted for, in order to 
compare results without additional variables in the treatment regimen of the two groups. 
In OA there is an overproduction of destructive substances and inflammation mediators that give 
rise to a balance in favor of articular cartilage catabolism [44]. The main problem with OA is pain, 
being the most common reason for consultation [10,44,45], but patients also present with stiffness, 
fatigue, walking limitations, discomfort, sleep disturbances, anxiety, and decreased quality of life [46]. 
Options for the treatment of OA vary considerably among authors [32] although biological therapies 
are a promising way of treating this disease, providing evident and lasting improvement that preserves 
tissue, improves the clinical signs and enhances articular function [47–50]. As mentioned, the objectives 
of treatment with regenerative therapies are the reduction of this parameter with consequent improvement 
of the functionality, using less aggressive therapies [51]. Both the application of aMSCs [22,52,53], 
and PRGF [32,54] demonstrate a decrease in the patient’s perception of pain. This effect is very 
important, as it has been shown that even after a joint replacement, 38% in hip and 53% in knee 
maintain some degree of pain one year after surgery [55]. Assessing the severity of lameness and pain 
due to OA is more challenging with canine patients than with human patients. The VAS scale has been 
used in previous studies [32,56], and are accepted methods for assessing pain. In this study, animals in 
both groups showed significant improvement in pain scores from the first month post treatment, 
perceived by both evaluators. So, with both therapies, one of the most important goals in the treatment 
of OA was achieved, the reduction of the pain experienced by patients in the affected area [10,57]. 
Furthermore, the beneficial effect achieved with both therapies was reflected in data provided by 
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owners in the treatment satisfaction questionnaires, where both treatments achieved a high degree of 
satisfaction from the first month post-treatment and maintained until the end of the study. 
OA is a degenerative disease that can affect all articular structures, causing joint degeneration with 
osteophyte formation, bone remodeling and alteration of periarticular tissues including the synovial 
fluid, joint capsule, subchondral bone, muscle, tendon and ligaments [58]. Among the methods of 
evaluation of this pathology, radiology is used as a simple technique for its availability and 
accessibility [59], although there is controversy as to its utility as a diagnostic method for the response 
to different treatments. It has been reported that OA in rabbits treated with mesenchymal cells derived 
from adipose tissue showed radiographic changes at 20 weeks post infiltration [60]. Contrary to a 
previous study [60], here, improvement in the signs of OA was not seen, however a progression of the 
signs was not seen either during the six month study, similar to those results observed in human [61] 
and veterinary studies where Silva et al. reported no significant differences in the radiographic exam 
between animals treated with PRP and control group after cranial cruciate ligament surgery [62]. The 
radiological analysis used in this study was inconclusive. One reason to explain these findings could be 
related to technical limitations for detecting and evaluating the progression of osteoarthritis in both 
groups, although radiographs were evaluated and scored in a multiple blind fashion. These results do 
not necessarily mean that changes did not exist at a cartilage structure level, but in order to 
demonstrate this, a magnetic resonance imaging (MRI) study should have been conducted to evaluate 
these structures in more detail or biopsies of the cartilage in affected joints should have been 
performed [63]. These complementary assessments were not performed due to the complications they 
implied for the owners.  
The ROM in joints affected by OA decreases significantly [8,57], producing a decrease in 
functionality that has a detrimental effect on the ability to lead a normal life [1]. It has been observed 
that treatments with aMSCs [8,22] and PRGF [5,10,32] enhance the functionality of joints affected by 
OA which leads to an improvement in clinical signs, reducing lameness and providing notable 
recovery of previously limited walking and running activities [8,52]. In this study, enhanced joint 
mobility and functionality were observed in both of the treatment groups, although there is a 
significantly greater improvement in the aMSCs group at 6 months post treatment. 
The effect PRGF has in the treatment of OA is due to the behavior of the platelet concentrate, acting 
as a scaffold which through the various growth factors promotes the stimulation of chondrogenesis, 
increases hyaluronic acid production, stabilizes angiogenesis and differentiation of the existing cells in 
the area treated [6,64]. Platelets are cells that contain many important bioactive proteins and growth 
factors (GFs) which are polypeptide substances, both soluble and diffusible, that regulate key 
processes in tissue repair, including cell proliferation, chemotaxis, migration, differentiation, and 
extracellular matrix synthesis [27,65,66]. The results of the current study coincide with those of 
numerous studies, both in vitro and in vivo, that have shown that PRP stimulates chondrocyte 
proliferation and matrix synthesis [67,68], and indicate that intra-articular injection of PRP prevents 
progression of osteoarthritis, improves articular function and reduces pain in the area [10,48,69]. 
However, with respect to the aMSCs, the effect is due to the contribution of culture expanded MSCs, 
which have the capacity for regeneration and differentiation into the various tissues involved, that is, 
new cells are provided that differentiate into cells at the injury site allowing for greater improvement  
in the area treated [70]. These types of cells express the potential to differentiate into multiple tissue 
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lineages such as osteogenic and chondrogenic phenotypes [71,72] and have the ability to localize  
and participate in the repair of damaged joint structures, including cruciate ligaments, menisci,  
and cartilage lesions [21]. Additionally, aMSCs are known for their anti-inflammatory and 
immunomodulatory properties and for being a safe therapy without adverse effects [52,60]. In this 
study both groups increased ROM from baseline; although aMSCs had worse scores at the beginning 
of the study, dogs treated with aMSCs reported increased ROM at 6 months after treatment. 
Thus based on the findings in this study, the therapeutic use of both PRGF and aMSCs are novel 
treatments that report goods results for overcoming the difficulties in regeneration of articular cartilage 
in OA while maintaining or improving the structure and joint function without the need for more 
aggressive techniques that can cause further damage to the organism. Mesenchymal cells are cell 
populations with molecular mechanisms capable of self-renewal and differentiation into various cell 
types in damaged tissue, repairing and supplying physiological functions in the affected joint, reducing 
pain, restoring joint function and delaying the onset of cartilage degradation [73–75]. In the case of 
PRGF, the proteins they contain have the ability to increase the proteoglycan and collagen synthesis by 
chondrocytes and regulate homeostasis and proper functioning of cartilage [75,76]. Notably, both 
PRGF and aMSCs improved the pathology at an articular level, with improvement to clinical signs and 
symptoms as well as to the structural damage caused by the disease [53,77]. Given that the animals in 
the current study showed significant improvement in all parameters studied but without obvious 
radiographic changes, it could be deduced that radiology may not be a sufficiently sensitive technique 
to assess the evolution of OA at the particular time points studied by the team of researchers in this 
parallel study [78]. 
In addition to OA, the beneficial effects of both treatments have also been described in Achilles 
tendon in a murine animal model and in facial nerve injury in a porcine experimental model, finding  
a synergistic effect on healing when PRP was used in combination with adult stem cells [79,80]. 
However, this synergistic effect was not demonstrated in a study on flexor tendons in sheep, where  
the group treated with MSCs showed an improvement in the composition and organization of the 
structural matrix, with increased expression of collagen I and cartilage oligomeric matrix protein, 
along with a decreased expression of collagen III, compared to the groups treated with PRP alone or in 
combination with MSC. The authors attributed the absence of the synergistic effect between the 
treatments to the possibility that the behavior and action exerted by each take completely different 
routes, or that protocols were not optimal for stimulation of this synergistic action [81]. 
Having demonstrated the therapeutic benefit of both treatments, one must take the advantages and 
disadvantages of each treatment’s clinical application into account. Although PRGF demonstrated  
a shorter duration of effect, it has the advantage of being substantially more affordable and far less 
invasive, and therefore simpler for ambulatory use. And it is important to highlight that PRGF 
treatment can be optimized with serial injections over time to obtain better results with respect to the 
duration of the effect [77].  
Regarding the aMSCs, the main drawback is the need to perform minor surgery under general 
anesthesia for harvesting adipose tissue, with the advantage being the greater therapeutic benefit 
achieved. The possibility of optimizing this treatment is the creation of a bank of autologous cells, 
allowing for their availability without the necessity of further surgeries. This would bring the treatment 
into the outpatient clinical setting [76].  
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Minimally invasive methods for the treatment of OA in dogs are appealing to both veterinarians and 
pet owners, particularly when compared with surgical alternatives such as joint replacement. 
The main limitations of this study include the lack of a placebo group, although recent studies have 
demonstrated that a single intra-articular injection of Saline Solution in OA dogs, has no effect in 
reducing pain or improving functionality [32]. It could be a very good option to have performed  
an MRI or a biopsy of the cartilage, and an arthrocentesis to collect synovial fluid at each visit. These 
complementary assessments were not performed due to the complications they implied for the owners. 
It is also true that the differences in the protocols makes it impossible to blind the treatment to the 
owner (dogs received a biopsy for the fat sample), but the evaluation of the dogs status and disease 
progression was performed by blinded physicians. 
So, to fully demonstrate the potential of these two therapies in the treatment of OA, more  
double-blind randomized controlled trials should be performed as histological results could be very 
important for the future of these treatments. These studies should include the determination of 
biological markers of articular catabolism and anabolism in the serum and synovial fluid, and 
arthroscopic and histological evaluation of the cartilage. 
3. Experimental Section  
3.1. Animal Population and Randomization 
The study was designed as a randomized, multicenter, blinded, parallel group, conducted in 3 veterinary 
hospitals. Dogs, male or female, with lameness of the legs were eligible for inclusion. A complete 
orthopedic and health history was collected as part of the screening and initial enrollment. Only dogs 
with hip OA were included in the study. A block randomization to either aMSCs or PRGF group was 
performed where an independent randomization coordinator, who was not responsible for determining 
the eligibility of the animals, included the animal and had no information about the dogs in the trial 
and no influence on the assignment sequence. All assignments were communicated by phone. 
The following diagnostic criteria for patient selection were used: Animals suffering from 
degenerative joint disease in one or both hips, weighing more than 15 kg and being free of concurrent 
pathologies apart from OA. Prior to inclusion, a complete clinical evaluation (physical examination 
and vital signs were taken), complete hematology and serum biochemistry, endocrine and serology 
panel were performed. Orthopedic radiographs were reviewed to determine the degree of osteoarthritis 
in the affected area using the Bioarth® scale (Bioiberica, S.A. Barcelona, Spain) for the hip joint, 
where the presence of OA was evaluated and evidenced by subchondral bone sclerosis, bone 
remodeling, osteophytes, or enthesophytes [82]. Once the animal completed the inclusion criteria, no 
treatments (non-steroidal anti-inflammatory drugs, analgesics, nutraceuticals, or adjunctive therapies) 
could be administered for two months. After this two month period, the animal was evaluated again as  
at baseline. 
Once the animal started the study, the exclusion criteria included any significant impairment of 
physical condition or functional status, whether as a result of the treatment, or for reasons beyond 
those previously mentioned (Figure 5). 
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All owners of participating dogs signed a written consent form where they were given relevant 
information about the study and agreed to the randomization procedure. There was one fixed price for 
all participants irrespective of the treatment given. The study was approved by the institutional animal 
care board at the Las Palmas de Gran Canaria School of Veterinary Science. 
After this, dogs were assigned to one of the following groups: 
o aMSCs: single intra-articular injection of autologous aMSCs (DogStem®, Fat-Stem, Aalst, 
Belgium) (2 mL containing 30 million aMSCs) (n = 18). 
o PRGF: single intra-articular injection of autologous PRGF (PRGF-Endoret®, BTI 
Biotechnology Institute, Vitoria-Gasteiz, Araba, Spain) (2 mL) (n = 19). 
Figure 5. Inclusion and exclusion criteria.  
 
As some animals were affected bilaterally, the total number of joints studied were 40 and 38 for the 
aMSCs and PRGF groups, respectively.  
After the injection, the owners of the dogs were instructed to check for any sign of discomfort or 
pain, and were given instructions on the administration of cephalosporin (20 mg/kg/12 h, PO 7 days), 
meloxicam (0.1 mg/kg/24 h, PO, 3 days), and tramadol 82.0 mg/kg/12 h, PO, 24 h). Throughout  
the study the owners could use meloxicam as a rescue analgesic, to be recorded in writing for  
further assessment. 
3.2. Treatments Applied 
3.2.1. aMSCs  
The entire sample collection process was approved and certified by the dog owners with a signed 
informed consent. A biopsy of 20 g of subcutaneous fat tissue was collected from the inguinal region 
through a small surgical incision, and 120 mL of blood was isolated under aseptic conditions and 
processed with the DogStem® kit (Fat-Stem, Aalst, Belgium). Immediately after sample collection, fat 
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biopsy and blood were sent at 4 °C for cell isolation and amplification under current GMP conditions 
to the Fat-Stem Laboratory (Aalst, Belgium).  
The adipose tissue was processed according to standardized Fat-Stem laboratory procedures and in 
accordance with the GMP laboratory regulations. The derived adipose tissue was digested enzymatically, 
washed and centrifuged several times to obtain a concentrate of cells. Subsequently, the mixture of 
cells was grown in a bioreactor environment with controlled temperature, oxygen and CO2 control. 
Parameters and conditions of growth were selected for the expansion of adult mesenchymal stem cells. 
Cultivation results showed that adjustments in cultivating conditions are necessary to optimize cell 
growth and to maintain the dog stem cells over several passages, e.g., autologous serum and/or 
additional growth factors. Different media settings have been tested on canine ASC during P1 to P4: 
Evaluation of the media was performed at 80% confluence of cells: 
• Morphology: cells are plastic adherent, lack osmotic shrinkage, normal cell surface and 
fibroblastic shape. 
• Ease of trypsinization: a single trypsinization. 
• Color of the cultivation medium: Phenol red indicator is used to evaluate pH changes, which 
might affect growth of the stem cells. 
• Proliferation time (doubling time): The population-doubling time (PDT) is defined as the time 
required for a colony area to expand twofold. Population doubling time calculates growth 
proliferation. PDT results are graphically visualized over passage time. 
• Viability: Viability of the cells were quantified using trypan blue and cell counting methods 
were used. 
• Cells were expanded and 30 million cells were used for clinical purpose. 
Once the cells were amplified, the Fat-Stem Laboratory sent them in a 2 mL sterile solution 
containing 30 million aMSCs. In all cases, the laboratory certified cell quality.  
3.2.2. PRGF 
In the literature there are a many products named PRP, with different compositions and 
characteristics. In this study PRGF was used. It is the most advanced autologous Platelet-Rich Plasma 
system. It is based on the activation of the patient’s own platelets for the stimulation and acceleration 
of tissue healing and regeneration. It is 100% biocompatible, autologous, versatile and safe with 
control over its activation and use and with a simple, fast protocol: one 8 min of centrifugation and  
20 min of preparation. Also, it does not contain leukocytes (avoiding proinflammatory activity), nor 
erythrocytes [25].  
In all cases, blood was collected under aseptic conditions in 4.5 mL citrate tubes as necessary, and 
then centrifuged for 8 min at 460× g, then activated with 5% of its volume with 10% calcium chloride. 
The PRGF was applied immediately after its preparation and in none of the cases later than one hour.  
3.3. Outcome Variables 
All the patients were evaluated at baseline (T0) and 1 (T1), 3 (T3) and 6 (T6) months’ follow-up 
under sedation with dexmedetomidine (5 µg/kg), morphine (0.2 mg/kg) and midazolam (0.1 mg/kg). 
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Each follow up assessed passive manual mobilization of the joint, degree of atrophy of muscles 
concerned with movement of the involved articulation, goniometric measurements of the range of 
movement, radiographs and analysis with the Bioarth® scale (Bioiberica, S.A. Barcelona, Spain), a 
subjective patient pain assessment by the veterinarian and owner, questionnaire to owners on 
functional limitation of the animal, and satisfaction with the treatments applied. 
3.3.1. Pain Assessment 
Global pain of the animals was assessed twice using a 0–100 mm VAS scale, where 0 mm signified 
“no pain”, and 100 mm marked “extreme pain” by both the owner and the investigator. 
The patient pain assessment of disease status was performed by the owner answering the question: 
“Considering all the ways the arthritis affects your pet, please indicate the amount of pain that you 
think your pet is suffering by marking an (X) through the line”: 0–100 mm VAS scale: on the left “no 
pain”, and on the right “extreme pain”. 
________________________________________________ 
No pain       Extreme pain 
The investigator global assessment of the patient was performed with the question: “make a global assessment 
of the patient’s disease status by marking an (X) on the line below:” 
0–100 mm VAS scale: left “no pain”, and right “extreme pain”. 
________________________________________________ 
No pain       Extreme pain 
Once the postoperative treatment had finished, and if the owner perceived pain in their pet, 
meloxicam could be administered orally and then recorded in a diary for further investigation. 
3.3.2. Bioarth Assessment Scale [82] 
This scale published for the assessment of osteoarthritis in hips was used for radiographic and 
functional assessment of each joint, in an independent manner [82]: 
• Radiological assessment quantifies radiographic signs of osteoarthritis in canine elbows, hips and 
knees. Classifies the degrees of osteoarthritis into 4 categories 1: no signs of OA (0–2 points),  
2: mild OA (3–8 points), 3: moderate OA (9–14 points), 4: severe OA (more than 14 points), 
based on a numerical assessment (0–3) of 7 anatomical points in the joint (limits of total  
score 0–21).  
• Functional assessment evaluates the 3 basic functional parameters: functional limitation, joint 
mobility and muscle atrophy. 
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o Functional limitation quantifies the weight-bearing or support of each extremity, changes in 
posture when standing still, signs of lameness when cold and when walking, endurance 
during walking and playing, endurance when going up stairs and strength limitations in 
small jumps (measurement scale: 0 to 23 points). 
o Joint mobility score is a summation of joint motion limitation, of the degree of flexion and 
extension of the joint studied (ROM: extension minus flexion) and pain when performing 
this assessment, with the goniometer (measurement scale: 0 to 7 points). 
o Muscle atrophy measured in centimeters, circumference of musculature at standard 
anatomical references. A measure ribbon was used taking three measurements and an 
average calculated. (Measurement scale: 0: no atrophy, 1: mild atrophy, 2: severe atrophy).  
3.3.3. Owner Satisfaction with the Treatment 
When the animals started the study, owners were asked about the treatments received. Overall 
satisfaction on the treatment were recorded and then compared with the results obtained after 6 months 
of the infiltration with aMSCs or PRGF. 
Outcomes in quality of life were also evaluated at baseline and at all the time points. These 
questions were scored on a five point Likert scale. For analysis, the responses were assigned numeric 
values 1 to 5, respectively. 





3.3.4. Safety Assessments 
The nature, onset, duration, severity and outcomes of all side effects were assessed and documented 
at each visit. To evaluate the safety profile of the two treatments, all complications and adverse events 
were recorded with an accountability scale.  
3.3.5. Requirement of Rescue Analgesia 
Throughout the study, owners could use meloxicam (0.1 mg/kg) as rescue analgesia if they thought 
that their pets required it. The owner recorded the use of rescue medication daily. 
3.4. Statistical Analysis 
Data were analyzed with the SPSS 20.0 program for MAC (IBM, Madrid, Spain, 2012). Data were 
assessed for normality with the Shapiro-Wilk test, and non-parametric Kruskal-Wallis and  
Mann-Whitney U tests were used to compare quantitative variables at each follow-up time point 
between groups. A related-samples Wilcoxon Signed Rank Test was used to assess differences with 
baseline in each group. Crosstabs with contingency coefficient or Fisher’s exact test were used to 
evaluate the categorical variables as necessary. For VAS score, the percentage change before 
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(baseline) versus after (1, 3, and 6 months) treatment was calculated for each group. A p-value < 0.05 
was considered statistically significant. 
4. Conclusions  
The findings in the current study show that aMSCs and PRGF are safe and effective in the 
functional analysis at 1, 3 and 6 months; a significant improvement was provided, reducing dogs’ pain, 
and improving physical function with respect to basal levels in patients with hip OA. Compared to 
PRGF, aMSCs showed better results at 6 months, though it is a more aggressive treatment when 
considering its procurement. Both treatments should be considered in the treatment of dogs with hip OA. 
Acknowledgments 
Thomas Michael Oxlee Translations-Editing.  
Author Contributions 
The Fundación García Cugat funded this study with funding provided by the Ministry of Health of 
the Government of Spain.  
Conflicts of Interest 
The authors declare no conflict of interest. 
References 
1. Juni, P.; Reichenbach, S.; Dieppe, P. Osteoarthritis: Rational approach to treating the individual. 
Best Pract. Res. Clin. Rheumatol. 2006, 20, 721–740. 
2. Malek, S.; Sample, S.J.; Schwartz, Z.; Nemke, B.; Jacobson, P.B.; Cozzi, E.M.; Schaefer, S.L.; 
Bleedorn, J.A.; Holzman, G.; Muir, P. Effect of analgesic therapy on clinical outcome measures in 
a randomized controlled trial using client-owned dogs with hip osteoarthritis. BMC Vet. Res. 
2012, 8, 185. doi:10.1186/1746-6148-8-185.  
3. Rychel, J.K. Diagnosis and treatment of osteoarthritis. Top. Companion Anim. Med. 2010, 25, 20–25. 
4. Egloff, C.; Hugle, T.; Valderrabano, V. Biomechanics and pathomechanisms of osteoarthritis. 
Swiss Med. Wkly. 2012, 142, w13583. doi:10.4414/smw.2012.13583. 
5. Vaquerizo, V.; Plasencia, M.A.; Arribas, I.; Seijas, R.; Padilla, S.; Orive, G.; Anitua, E. 
Comparison of intra-articular injections of plasma rich in growth factors (prgf-endoret) versus 
durolane hyaluronic acid in the treatment of patients with symptomatic osteoarthritis: A 
randomized controlled trial. Arthroscopy 2013, 29, 1635–1643. 
6. Singh, J.A. Stem cells and other innovative intra-articular therapies for osteoarthritis: What does 
the future hold? BMC Med. 2012, 10, 44. doi:10.1186/1741-7015-10-44. 
7. Wu, L.; Cai, X.; Zhang, S.; Karperien, M.; Lin, Y. Regeneration of articular cartilage by adipose 
tissue derived mesenchymal stem cells: Perspectives from stem cell biology and molecular 
medicine. J. Cell. Physiol. 2013, 228, 938–944. 
Int. J. Mol. Sci. 2014, 15 13456 
 
 
8. Black, L.L.; Gaynor, J.; Adams, C.; Dhupa, S.; Sams, A.E.; Taylor, R.; Harman, S.; Gingerich, D.A.; 
Harman, R. Effect of intraarticular injection of autologous adipose-derived mesenchymal stem 
and regenerative cells on clinical signs of chronic osteoarthritis of the elbow joint in dogs. Vet. Ther. 
2008, 9, 192–200. 
9. Wu, W.; Chen, F.; Liu, Y.; Ma, Q.; Mao, T. Autologous injectable tissue-engineered cartilage by 
using platelet-rich plasma: Experimental study in a rabbit model. J. Oral Maxillofac. Surg. 2007, 
65, 1951–1957. 
10. Wang-Saegusa, A.; Cugat, R.; Ares, O.; Seijas, R.; Cusco, X.; Garcia-Balletbo, M. Infiltration of 
plasma rich in growth factors for osteoarthritis of the knee short-term effects on function and 
quality of life. Arch. Orthop. Trauma Surg. 2011, 131, 311–317. 
11. Raghunath, J.; Salacinski, H.J.; Sales, K.M.; Butler, P.E.; Seifalian, A.M. Advancing cartilage tissue 
engineering: The application of stem cell technology. Curr. Opin. Biotechnol. 2005, 16, 503–509. 
12. Oldershaw, R.A. Cell sources for the regeneration of articular cartilage: The past, the horizon and 
the future. Int. J. Exp. Pathol. 2012, 93, 389–400. 
13. Mizuno, H.; Tobita, M.; Uysal, A.C. Concise review: Adipose-derived stem cells as a novel tool 
for future regenerative medicine. Stem Cells 2012, 30, 804–810. 
14. Timmins, N.E.; Kiel, M.; Gunther, M.; Heazlewood, C.; Doran, M.R.; Brooke, G.; Atkinson, K. 
Closed system isolation and scalable expansion of human placental mesenchymal stem cells. 
Biotechnol. Bioeng. 2012, 109, 1817–1826. 
15. Yang, S.; Huang, S.; Feng, C.; Fu, X. Umbilical cord-derived mesenchymal stem cells: Strategies, 
challenges, and potential for cutaneous regeneration. Front. Med. 2012, 6, 41–47. 
16. Jackson, W.M.; Lozito, T.P.; Djouad, F.; Kuhn, N.Z.; Nesti, L.J.; Tuan, R.S. Differentiation and 
regeneration potential of mesenchymal progenitor cells derived from traumatized muscle tissue.  
J. Cell. Mol. Med. 2011, 15, 2377–2388. 
17. Jones, B.A.; Pei, M. Synovium-derived stem cells: A tissue-specific stem cell for cartilage 
engineering and regeneration. Tissue Eng. Part B Rev. 2012, 18, 301–311. 
18. Jones, E.A.; Crawford, A.; English, A.; Henshaw, K.; Mundy, J.; Corscadden, D.; Chapman, T.; 
Emery, P.; Hatton, P.; McGonagle, D. Synovial fluid mesenchymal stem cells in health and early 
osteoarthritis: Detection and functional evaluation at the single-cell level. Arthritis Rheumatol. 
2008, 58, 1731–1740. 
19. Yarak, S.; Okamoto, O.K. Human adipose-derived stem cells: Current challenges and clinical 
perspectives. An. Bras. Dermatol. 2010, 85, 647–656. 
20. Rodríguez-Jiménez, F.J.; Valdes-Sánchez, T.; Carrillo, J.M.; Rubio, M.; Monleon-Prades, M.; 
García-Cruz, D.M.; García, M.; Cugat, R.; Moreno-Manzano, V. Platelet-rich plasma favors 
proliferation of canine adipose-derived mesenchymal stem cells in methacrylate-endcapped 
caprolactone porous scaffold niches. J. Funct. Biomater. 2012, 3, 556–568. 
21. Agung, M.; Ochi, M.; Yanada, S.; Adachi, N.; Izuta, Y.; Yamasaki, T.; Toda, K. Mobilization of 
bone marrow-derived mesenchymal stem cells into the injured tissues after intraarticular injection 
and their contribution to tissue regeneration. Knee Surg. Sports Traumatol. Arthrosc. 2006, 14, 
1307–1314. 
  
Int. J. Mol. Sci. 2014, 15 13457 
 
 
22. Vilar, J.M.; Morales, M.; Santana, A.; Spinella, G.; Rubio, M.; Cuervo, B.; Cugat, R.; Carrillo, J.M. 
Controlled, blinded force platform analysis of the effect of intraarticular injection of autologous 
adipose-derived mesenchymal stem cells associated to prgf-endoret in osteoarthritic dogs.  
BMC Vet. Res. 2013, 9, 131. doi:10.1186/1746-6148-9-131. 
23. Bubnov, R.; Yevseenko, V.; Semeniv, I. Ultrasound guided injections of platelets rich plasma for 
muscle injury in professional athletes. Comparative study. Med. Ultrason. 2013, 15, 101–105. 
24. Grageda, E.; Lozada, J.L.; Boyne, P.J.; Caplanis, N.; McMillan, P.J. Bone formation in the 
maxillary sinus by using platelet-rich plasma: An experimental study in sheep. J. Oral Implantol. 
2005, 31, 2–17. 
25. Marx, R.E. Platelet-rich plasma: Evidence to support its use. J. Oral Maxillofac. Surg. 2004, 62, 
489–496. 
26. Pietrzak, W.S.; Eppley, B.L. Platelet rich plasma: Biology and new technology. J. Craniofac. Surg. 
2005, 16, 1043–1054. 
27. Anitua, E.; Andia, I.; Ardanza, B.; Nurden, P.; Nurden, A.T. Autologous platelets as a source of 
proteins for healing and tissue regeneration. Thromb. Haemost. 2004, 91, 4–15. 
28. Anitua, E.; Sanchez, M.; Orive, G.; Andia, I. The potential impact of the preparation rich in 
growth factors (prgf) in different medical fields. Biomaterials 2007, 28, 4551–4560. 
29. Park, Y.G.; Han, S.B.; Song, S.J.; Kim, T.J.; Ha, C.W. Platelet-rich plasma therapy for knee joint 
problems: Review of the literature, current practice and legal perspectives in korea. Knee Surg. 
Relat. Res. 2012, 24, 70–78. 
30. Velnar, T.; Bailey, T.; Smrkolj, V. The wound healing process: An overview of the cellular and 
molecular mechanisms. J. Int. Med. Res. 2009, 37, 1528–1542. 
31. Filardo, G.; Kon, E.; Pereira Ruiz, M.T.; Vaccaro, F.; Guitaldi, R.; di Martino, A.; Cenacchi, A.; 
Fornasari, P.M.; Marcacci, M. Platelet-rich plasma intra-articular injections for cartilage 
degeneration and osteoarthritis: Single- versus double-spinning approach. Knee Surg. Sports 
Traumatol. Arthrosc. 2012, 20, 2082–2091. 
32. Fahie, M.A.; Ortolano, G.A.; Guercio, V.; Schaffer, J.A.; Johnston, G.; Au, J.; Hettlich, B.A.; Phillips, T.; 
Allen, M.J.; Bertone, A.L. A randomized controlled trial of the efficacy of autologous platelet therapy 
for the treatment of osteoarthritis in dogs. J. Am. Vet. Med. Assoc. 2013, 243, 1291–1297. 
33. Tuan, R.S.; Boland, G.; Tuli, R. Adult mesenchymal stem cells and cell-based tissue engineering. 
Arthritis Res. Ther. 2003, 5, 32–45. 
34. Mizuno, H. Adipose-derived stem cells for tissue repair and regeneration: Ten years of research 
and a literature review. J. Nippon Med. Sch. 2009, 76, 56–66. 
35. Bigham-Sadegh, A.; Mirshokraei, P.; Karimi, I.; Oryan, A.; Aparviz, A.; Shafiei-Sarvestani, Z. 
Effects of adipose tissue stem cell concurrent with greater omentum on experimental long-bone 
healing in dog. Connect. Tissue Res. 2012, 53, 334–342. 
36. Haghighat, A.; Akhavan, A.; Hashemi-Beni, B.; Deihimi, P.; Yadegari, A.; Heidari, F. Adipose 
derived stem cells for treatment of mandibular bone defects: An autologous study in dogs.  
Dent. Res. J. 2011, 8, S51–S57. 
37. Chung, C.S.; Fujita, N.; Kawahara, N.; Yui, S.; Nam, E.; Nishimura, R. A comparison of 
neurosphere differentiation potential of canine bone marrow-derived mesenchymal stem cells and 
adipose-derived mesenchymal stem cells. J. Vet. Med. Sci. 2013, 75, 879–886. 
Int. J. Mol. Sci. 2014, 15 13458 
 
 
38. Martinello, T.; Bronzini, I.; Maccatrozzo, L.; Mollo, A.; Sampaolesi, M.; Mascarello, F.; 
Decaminada, M.; Patruno, M. Canine adipose-derived-mesenchymal stem cells do not lose stem 
features after a long-term cryopreservation. Res. Vet. Sci. 2011, 91, 18–24. 
39. Reich, C.M.; Raabe, O.; Wenisch, S.; Bridger, P.S.; Kramer, M.; Arnhold, S. Isolation, culture 
and chondrogenic differentiation of canine adipose tissue- and bone marrow-derived mesenchymal 
stem cells—A comparative study. Vet. Res. Commun. 2012, 36, 139–148. 
40. Kang, B.J.; Ryu, H.H.; Park, S.S.; Koyama, Y.; Kikuchi, M.; Woo, H.M.; Kim, W.H.; Kweon, O.K. 
Comparing the osteogenic potential of canine mesenchymal stem cells derived from adipose 
tissues, bone marrow, umbilical cord blood, and wharton’s jelly for treating bone defects.  
J. Vet. Sci. 2012, 13, 299–310. 
41. Guercio, A.; di Marco, P.; Casella, S.; Cannella, V.; Russotto, L.; Purpari, G.; di Bella, S.; Piccione, G. 
Production of canine mesenchymal stem cells from adipose tissue and their application in dogs with 
chronic osteoarthritis of the humeroradial joints. Cell Biol. Int. 2012, 36, 189–194. 
42. Oh, H.J.; Park, E.J.; Lee, S.Y.; Soh, J.W.; Kong, I.S.; Choi, S.W.; Ra, J.C.; Kang, S.K.; Lee, B.C. 
Comparison of cell proliferation and epigenetic modification of gene expression patterns in canine 
foetal fibroblasts and adipose tissue-derived mesenchymal stem cells. Cell Prolif. 2012, 45, 438–444. 
43. Dhillon, M.; Patel, S.; Bali, K. Comment on: Platelet-rich plasma intra-articular knee injections 
for the treatment of degenerative cartilage lesions and osteoarthritis. Knee Surg. Sports 
Traumatol. Arthrosc. 2011, 19, 863–864; author reply 865–866.  
44. Kapoor, M.; Martel-Pelletier, J.; Lajeunesse, D.; Pelletier, J.P.; Fahmi, H. Role of proinflammatory 
cytokines in the pathophysiology of osteoarthritis. Nat. Rev. Rheumatol. 2011, 7, 33–42. 
45. Wieland, H.A.; Michaelis, M.; Kirschbaum, B.J.; Rudolphi, K.A. Osteoarthritis—An untreatable 
disease? Nat. Rev. Drug Discov. 2005, 4, 331–344. 
46. Lane, N.E.; Brandt, K.; Hawker, G.; Peeva, E.; Schreyer, E.; Tsuji, W.; Hochberg, M.C. Oarsi-fda 
initiative: Defining the disease state of osteoarthritis. Osteoarthr. Cartil. 2011, 19, 478–482. 
47. Mifune, Y.; Matsumoto, T.; Takayama, K.; Ota, S.; Li, H.; Meszaros, L.B.; Usas, A.; Nagamune, K.; 
Gharaibeh, B.; Fu, F.H.; et al. The effect of platelet-rich plasma on the regenerative therapy of 
muscle derived stem cells for articular cartilage repair. Osteoarthr. Cartil. 2013, 21, 175–185. 
48. Kon, E.; Buda, R.; Filardo, G.; di Martino, A.; Timoncini, A.; Cenacchi, A.; Fornasari, P.M.; 
Giannini, S.; Marcacci, M. Platelet-rich plasma: Intra-articular knee injections produced favorable 
results on degenerative cartilage lesions. Knee Surg. Sports Traumatol. Arthrosc. 2010, 18, 472–479. 
49. Guilak, F.; Awad, H.A.; Fermor, B.; Leddy, H.A.; Gimble, J.M. Adipose-derived adult stem cells 
for cartilage tissue engineering. Biorheology 2004, 41, 389–399. 
50. Rada, T.; Reis, R.L.; Gomes, M.E. Distinct stem cells subpopulations isolated from human adipose 
tissue exhibit different chondrogenic and osteogenic differentiation potential. Stem Cell Rev. 
2011, 7, 64–76. 
51. Ringe, J.; Burmester, G.R.; Sittinger, M. Regenerative medicine in rheumatic disease-progress in 
tissue engineering. Nat. Rev. Rheumatol. 2012, 8, 493–498. 
52. Black, L.L.; Gaynor, J.; Gahring, D.; Adams, C.; Aron, D.; Harman, S.; Gingerich, D.A.; Harman, R. 
Effect of adipose-derived mesenchymal stem and regenerative cells on lameness in dogs with 
chronic osteoarthritis of the coxofemoral joints: A randomized, double-blinded, multicenter, 
controlled trial. Vet. Ther. 2007, 8, 272–284. 
Int. J. Mol. Sci. 2014, 15 13459 
 
 
53. Emadedin, M.; Aghdami, N.; Taghiyar, L.; Fazeli, R.; Moghadasali, R.; Jahangir, S.; Farjad, R.; 
Baghaban Eslaminejad, M. Intra-articular injection of autologous mesenchymal stem cells in six 
patients with knee osteoarthritis. Arch. Iran. Med. 2012, 15, 422–428. 
54. Filardo, G.; Kon, E.; Buda, R.; Timoncini, A.; di Martino, A.; Cenacchi, A.; Fornasari, P.M.; 
Giannini, S.; Marcacci, M. Platelet-rich plasma intra-articular knee injections for the treatment of 
degenerative cartilage lesions and osteoarthritis. Knee Surg. Sports Traumatol. Arthrosc. 2011, 
19, 528–535. 
55. Liu, S.S.; Buvanendran, A.; Rathmell, J.P.; Sawhney, M.; Bae, J.J.; Moric, M.; Perros, S.;  
Pope, A.J.; Poultsides, L.; della Valle, C.J.; et al. A cross-sectional survey on prevalence and risk 
factors for persistent postsurgical pain 1 year after total hip and knee replacement. Reg. Anesth. 
Pain Med. 2012, 37, 415–422. 
56. Hudson, J.T.; Slater, M.R.; Taylor, L.; Scott, H.M.; Kerwin, S.C. Assessing repeatability and 
validity of a visual analogue scale questionnaire for use in assessing pain and lameness in dogs. 
Am. J. Vet. Res. 2004, 65, 1634–1643. 
57. Pak, J. Regeneration of human bones in hip osteonecrosis and human cartilage in knee 
osteoarthritis with autologous adipose-tissue-derived stem cells: A case series. J. Med. Case Rep. 
2011, 5, 296. doi:10.1186/1752-1947-5-296. 
58. Van der Kraan, P.M. Osteoarthritis year 2012 in review: Biology. Osteoarthr. Cartil. 2012, 20, 
1447–1450. 
59. Braun, H.J.; Gold, G.E. Diagnosis of osteoarthritis: Imaging. Bone 2012, 51, 278–288. 
60. Toghraie, F.; Razmkhah, M.; Gholipour, M.A.; Faghih, Z.; Chenari, N.; Torabi Nezhad, S.; 
Nazhvani Dehghani, S.; Ghaderi, A. Scaffold-free adipose-derived stem cells (ascs) improve 
experimentally induced osteoarthritis in rabbits. Arch. Iran. Med. 2012, 15, 495–499. 
61. Kon, E.; Filardo, G.; Matteo, B.D.; Marcacci, M. Prp for the treatment of cartilage pathology. 
Open Orthop. J. 2013, 7, 120–128. 
62. Silva, R.F.; Carmona, J.U.; Rezende, C.M. Intra-articular injections of autologous platelet 
concentrates in dogs with surgical reparation of cranial cruciate ligament rupture. A pilot study. 
Vet. Comp. Orthop. Traumatol. 2013, 26, 285–290. 
63. Roemer, F.W.; Crema, M.D.; Trattnig, S.; Guermazi, A. Advances in imaging of osteoarthritis 
and cartilage. Radiology 2011, 260, 332–354. 
64. Xie, X.; Wang, Y.; Zhao, C.; Guo, S.; Liu, S.; Jia, W.; Tuan, R.S.; Zhang, C. Comparative 
evaluation of mscs from bone marrow and adipose tissue seeded in prp-derived scaffold for 
cartilage regeneration. Biomaterials 2012, 33, 7008–7018. 
65. Molloy, T.; Wang, Y.; Murrell, G. The roles of growth factors in tendon and ligament healing. 
Sports Med. 2003, 33, 381–394. 
66. Staudenmaier, R.; Froelich, K.; Birner, M.; Kindermann, J.; The Hoang, N.; Pueschel, R.C.; 
Mandlik, V. Optimization of platelet isolation and extraction of autogenous tgf-β in cartilage 
tissue engineering. Artif. Cells Blood Substit. Immobil. Biotechnol. 2009, 37, 265–272. 
67. Akeda, K.; An, H.S.; Okuma, M.; Attawia, M.; Miyamoto, K.; Thonar, E.J.; Lenz, M.E.; Sah, R.L.; 
Masuda, K. Platelet-rich plasma stimulates porcine articular chondrocyte proliferation and matrix 
biosynthesis. Osteoarthr. Cartil. 2006, 14, 1272–1280. 
Int. J. Mol. Sci. 2014, 15 13460 
 
 
68. Serra, C.I.; Soler, C.; Carillo, J.M.; Sopena, J.J.; Redondo, J.I.; Cugat, R. Effect of autologous 
platelet-rich plasma on the repair of full-thickness articular defects in rabbits. Knee Surg. Sports 
Traumatol. Arthrosc. 2013, 21, 1730–1736. 
69. Sampson, S.; Reed, M.; Silvers, H.; Meng, M.; Mandelbaum, B. Injection of platelet-rich plasma 
in patients with primary and secondary knee osteoarthritis: A pilot study. Am. J. Phys. Med. Rehabil. 
2010, 89, 961–969. 
70. Hildner, F.; Albrecht, C.; Gabriel, C.; Redl, H.; van Griensven, M. State of the art and future 
perspectives of articular cartilage regeneration: A focus on adipose-derived stem cells and 
platelet-derived products. J. Tissue Eng. Regen. Med. 2011, 5, e36–e51. 
71. Strem, B.M.; Hicok, K.C.; Zhu, M.; Wulur, I.; Alfonso, Z.; Schreiber, R.E.; Fraser, J.K.;  
Hedrick, M.H. Multipotential differentiation of adipose tissue-derived stem cells. Keio J. Med. 
2005, 54, 132–141. 
72. Pountos, I.; Jones, E.; Tzioupis, C.; McGonagle, D.; Giannoudis, P.V. Growing bone and 
cartilage. The role of mesenchymal stem cells. J. Bone Jt. Surg. 2006, 88, 421–426. 
73. Roberts, S.; Genever, P.; McCaskie, A.; de Bari, C. Prospects of stem cell therapy in 
osteoarthritis. Regen. Med. 2011, 6, 351–366. 
74. Singer, N.G.; Caplan, A.I. Mesenchymal stem cells: Mechanisms of inflammation. Annu. Rev. Pathol. 
2011, 6, 457–478. 
75. Khan, W.S.; Johnson, D.S.; Hardingham, T.E. The potential of stem cells in the treatment of knee 
cartilage defects. Knee 2010, 17, 369–374. 
76. Fortier, L.A.; Barker, J.U.; Strauss, E.J.; McCarrel, T.M.; Cole, B.J. The role of growth factors in 
cartilage repair. Clin. Orthop. Relat. Res. 2011, 469, 2706–2715. 
77. Andia, I.; Sanchez, M.; Maffulli, N. Joint pathology and platelet-rich plasma therapies.  
Expert Opin. Biol. Ther. 2012, 12, 7–22. 
78. Cromer, M.S.; Bourne, R.M.; Fransen, M.; Fulton, R.; Wang, S.C. Responsiveness of quantitative 
cartilage measures over one year in knee osteoarthritis: Comparison of radiography and mri 
assessments. J. Magn. Reson. Imaging 2014, 39, 103–109. 
79. Chen, L.; Dong, S.W.; Liu, J.P.; Tao, X.; Tang, K.L.; Xu, J.Z. Synergy of tendon stem cells and 
platelet-rich plasma in tendon healing. J. Orthop. Res. 2012, 30, 991–997. 
80. Cho, H.H.; Jang, S.; Lee, S.C.; Jeong, H.S.; Park, J.S.; Han, J.Y.; Lee, K.H.; Cho, Y.B. Effect of 
neural-induced mesenchymal stem cells and platelet-rich plasma on facial nerve regeneration in 
an acute nerve injury model. Laryngoscope 2010, 120, 907–913. 
81. Patruno, M.; Martinello, T. Treatments of the injured tendon in veterinary medicine: From 
scaffolds to adult stem cells. Histol. Histopathol. 2014, 29, 417–422. 
82. Sanchez-Carmona, A.; Agut, A.; Chico, A.; Closa, J.M.; Rial, J.; Velasco, A. Desarrollo de una 
escala de valoración radiológica del grado de osteoartrosis para las articulaciones de la rodilla y el 
codo en el perro—Escala “BIOARTH”. Revista oficial de la Asociación Veterinaria Española de 
Especialistas en Pequeños Animales, AVEPA 2006, 26, 269–275. (In Spanish) 
© 2014 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article 
distributed under the terms and conditions of the Creative Commons Attribution license 
(http://creativecommons.org/licenses/by/3.0/). 
